Follicular lymphoma: a historical overview

References

• Virchow R. Cellular Pathology as Based Upon Physiological and Pathological Pathology, 1st ed. Robert M. Dewitt, New York 1859
   Google Scholar
• Cohnheim J. Ein Fall von Pseudoleukämie. Virchows Arch 1862; 33: 451–454
   Google Scholar
• Magrath I T. Historical perspective: the evolution of modern concepts of biology and management. The Non-Hodgkin's Lymphomas, 2nd ed, I T Magrath. Arnold, London 1997; 47–76
   Google Scholar
• Brill N E, Baehr G, Rosenthal N. Generalized giant lymph follicle hyperplasia of lymph nodes and spleen. JAMA 1925; 84: 668–670
   Google Scholar
• Symmers D. Follicular lymphadenopathy with splenomegaly. Arch Pathol Lab Med 1927; 3: 820
   Google Scholar
• Jackson H. The classification and prognosis of Hodgkin's disease and allied disorders. Surg Gynecol Obstet 1937; lxiv: 465
   Google Scholar
• Gall E A, Morrison H R, Scott A T. The follicular type of malignant lymphoma: a survey of 63 cases. Ann Int Med 1941; 14: 2073–2083
   Google Scholar
• Ryan D H, Cohen H J. Bone marrow aspiration and morphology. Hematology, Basic Principles and Practice, 3rd ed, R Hoffman, E J Benz, S J Shattil, B Furie, H J Cohen, L E Silberstein, et al. Churchill Livingstone, New York 2000; 2460–2468
   Google Scholar
• Rappaport H, Winter W J, Hicks E B. Follicular lymphoma: a reevaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956; 9: 792–821
   PubMed Web of Science ®Google Scholar
• Bosga-Bouwer A G, van den B A, Haralambieva E, de J D, Boonstra R, Kluin P, et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?. Hum Pathol 2006; 37: 528–533
   PubMed Web of Science ®Google Scholar
• Gall E A, Mallory T B. Malignant lymphoma, a clinico-pathologic survey of 618 cases. Am J Pathol 1942; 18: 381–429
   PubMedGoogle Scholar
• Biagi J J, Seymour J F. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 2002; 99: 4265–4275
   PubMed Web of Science ®Google Scholar
• Seligmann M, Grouet J C, Preud'homme C. The immunological diagnosis of human leukemias and lymphomas. An overview. Immunological Diagnosis of Leukemias and Lymphomas, S Thierfelder, H Rodt, E Thiel. Springer Verlag, Berlin 1977; 1–16
   Google Scholar
• Jaffe E S, Shevach E M, Frank M M, Berard C W, Green I. Nodular lymphoma – evidence for origin from follicular B lymphocytes. N Engl J Med 1974; 290: 813–819
   PubMed Web of Science ®Google Scholar
• Glick A D, Leech J H, Waldron J A, Flexner J M, Horn R G, Collins R D. Malignant lymphomas of follicular center cell origin in man. II. Ultrastructural and cytochemical studies. J Nat Cancer Inst 1975; 54: 23–36
   PubMed Web of Science ®Google Scholar
• Leech J H, Glick A D, Waldron J A, Flexner J M, Horn R G, Collins R D. Malignant lymphomas of follicular center cell origin in man. I. Immunologic studies. J Nat Cancer Inst 1975; 54: 11–21
   PubMed Web of Science ®Google Scholar
• Harris N L, Nadler L M, Bhan A K. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities. Am J Pathol 1984; 117: 262–272
   PubMed Web of Science ®Google Scholar
• Yunis J J, Oken M M, Kaplan M E, Ensrud K M, Howe R R, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982; 307: 1231–1236
   PubMed Web of Science ®Google Scholar
• Horsman D E, Gascoyne R D, Coupland R W, Coldman A J, Adomat S A. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma. Am J Clin Pathol 1995; 103: 472–478
   PubMed Web of Science ®Google Scholar
• Knutsen T. Cytogenetic mechanisms in the pathogenesis and progression of follicular lymphoma. Cancer Surv 1997; 30: 163–192
   PubMedGoogle Scholar
• Cleary M L, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439–7443
   PubMed Web of Science ®Google Scholar
• Korsmeyer S J, McDonnell T J, Nunez G, Hockenbery D, Young R. bcl-2: B cell life, death and neoplasia. Curr Top Microbiol Immunol 1990; 166: 203–207
   PubMed Web of Science ®Google Scholar
• McDonnell T J, Nunez G, Platt F M, Hockenberry D, London L, McKearn J P, et al. Deregulated bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol Cell Biol 1990; 10: 1901–1907
   PubMed Web of Science ®Google Scholar
• McDonnell T J, Deane N, Platt F M, Nunez G, Jaeger U, McKearn J P, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79–88
   PubMed Web of Science ®Google Scholar
• McDonnell T J, Korsmeyer S J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991; 349: 254–256
   PubMed Web of Science ®Google Scholar
• Hoglund M, Sehn L, Connors J M, Gascoyne R D, Siebert R, Sall T, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 2004; 39: 195–204
   PubMed Web of Science ®Google Scholar
• De Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23: 6358–6363
   PubMed Web of Science ®Google Scholar
• Quesada J R, Hawkins M, Horning S J, Alexanian R, Borden T, Merigan T, et al. A collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 1984; 77: 427–432
   PubMed Web of Science ®Google Scholar
• Bahler D W, Levy R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc Natl Acad Sci USA 1992; 89: 6770–6774
   PubMed Web of Science ®Google Scholar
• Zelenetz A D, Campbell M J, Bahler D W, Takahashi S, Oren R, Esserman L, et al. Follicular lymphoma: a model of lymphoid tumor progression in man. Ann Oncol 1991; 2(Suppl 2)115–122
   PubMed Web of Science ®Google Scholar
• Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider B F, Shumansky K, Spinelli J J, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169–2174
   PubMed Web of Science ®Google Scholar
• McLaughlin P. Progress and promise in the treatment of indolent lymphomas. Oncologist 2002; 7: 217–225
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, rranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Rohatiner A Z, Gregory W M, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223
   PubMed Web of Science ®Google Scholar
• Schouten H C, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson H E, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927
   PubMed Web of Science ®Google Scholar
• Fisher R I, LeBlanc M, Press O W, Maloney D G, Unger J M, Miller T P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–8452
   PubMed Web of Science ®Google Scholar
• Paryani S B, Hoppe R T, Cox R S, Colby T V, Kaplan H S. The role of radiation therapy in the management of stage III follicular lymphomas. J Clin Oncol 1984; 2: 841–848
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Fuller L M, Velasquez W S, Sullivan-Halley J A, Butler J J, Cabanillas F. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58: 1596–1602
   PubMed Web of Science ®Google Scholar
• Monfardini S, Banfi A, Bonadonna G, Rilke F, Milani F, Valagussa P, et al. Improved 5-year survival after combined radiotherapy-chemotherapy for Stage I-II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1980; 6: 125–134
   PubMed Web of Science ®Google Scholar
• Peters M. The contribution of radiation therapy in the control of early lymphomas. Am J Roentgenol Radium Ther Nucl Med 1963; 90: 956–967
   PubMedGoogle Scholar
• Cox J D, Komaki R, Kun L E, Wilson J F, Greenberg M. Stage III nodular lymphoreticular tumors (non-Hodgkin's lymphoma): results of central lymphatic irradiation. Cancer 1981; 47: 2247–2252
   PubMed Web of Science ®Google Scholar
• Glatstein E, Fuks Z, Goffinet D R, Kaplan H S. Non-Hodgkin's lymphomas of stage III extent. Is total lymphoid irradiation appropriate treatment?. Cancer 1976; 37: 2806–2812
   PubMed Web of Science ®Google Scholar
• Ha C S, Kong J S, Tucker S L, McLaughlin P, Wilder R B, Hess M A, et al. Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study. Int J Radiat Oncol Biol Phys 2003; 57: 316–320
   PubMed Web of Science ®Google Scholar
• Frei E. Acute leukemia in children. Model for the development of scientific methodology for clinical therapeutic research in cancer. Cancer 1984; 53: 2013–2025
   PubMed Web of Science ®Google Scholar
• Frei E, III. Curative cancer chemotherapy. Cancer Res 1985; 45: 6523–6537
   PubMed Web of Science ®Google Scholar
• Horning S J. Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881–884
   PubMed Web of Science ®Google Scholar
• Young R C, Longo D L, Glatstein E, Ihde D C, Jaffe E S, DeVita V T, Jr. The treatment of indolent lymphomas: watchful waiting vs. aggressive combined modality treatment. Semin Hematol 1988; 25: 11–16
   PubMed Web of Science ®Google Scholar
• Ardeshna K M, Smith P, Norton A, Hancock B W, Hoskin P J, MacLennan K A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516–522
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no treatment-policy, prednimustine, or interferon alfa: a randomized study from the groupe d'etude des lymphomes folliculaires. J Clin Oncol 1997; 15: 1110–1117
   PubMed Web of Science ®Google Scholar
• Denham J W, Denham E, Dear K B, Hudson G V. The follicular non-Hodgkin's lymphomas. I. The possibility of cure. Eur J Cancer A 1996; 32: 470–479
   Web of Science ®Google Scholar
• Kimby E, Bjorkholm M, Gahrton G, Glimelius B, Hagberg H, Johansson B, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994; 5(Suppl 2)67–71
   PubMedGoogle Scholar
• Peterson B A, Petroni G R, Frizzera G, Barcos M, Bloomfield C D, Nissen N I, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol 2003; 21: 5–15
   PubMed Web of Science ®Google Scholar
• Coiffier B, Neidhardt-Berard E M, Tilly H, Belanger C, Bouabdallah R, Haioun C, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 1999; 10: 1191–1197
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin P J, De Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 1590–1596
   PubMed Web of Science ®Google Scholar
• Krim M. Towards tumor therapy with interferons, Part 2: Interferons: in vivo effects. Blood 1980; 55: 875–884
   PubMed Web of Science ®Google Scholar
• Priestman T J. Interferon: an anti-cancer agent?. Cancer Treat Rev 1979; 6: 223–237
   PubMed Web of Science ®Google Scholar
• Borden E C. Interferons: rationale for clinical trials in neoplastic disease. Ann Intern Med 1979; 91: 472–479
   PubMed Web of Science ®Google Scholar
• Gutterman J U, Blumenschein G, Alexanian R. leucocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 1980; 93: 399–406
   PubMed Web of Science ®Google Scholar
• Foon K A, Sherwin S A, Abrams P G, Longo D L, Fer M F, Stevenson H C, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311: 1148–1152
   PubMed Web of Science ®Google Scholar
• O'Connell M J, Colgan J P, Oken M M, Ritts R E, Jr, Kay N E, Itri L M. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphoma and chronic lymphocytic leukemia. An ECOG pilot study. J Clin Oncol 1986; 4: 128–136
   PubMed Web of Science ®Google Scholar
• Wagstaff J, Loynds P, Crowther D. A phase II study of human recombinant DNA-a2 interferon in patients with low-grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1986; 18: 54–58
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329: 1608–1614
   PubMed Web of Science ®Google Scholar
• Smalley R V, Andersen J W, Hawkins M J, Bhide V, O'Connell M J, Oken M M, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1336–1341
   PubMed Web of Science ®Google Scholar
• Andersen J W, Smalley R V. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up. N Engl J Med 1993; 329: 1821–1822
   PubMed Web of Science ®Google Scholar
• Unterhalt M, Hermann R, Koch P, Trumper L, Bodenstein H, Dietzfelbinger H, et al. Long term interferon α maintenance prolongs remission duration in advanced low grade lymphoma and is related to the efficacy of initial cytoreductive therapy. Anonymous. 1996; 453a, Abstract
   Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 1993; 329: 1608–1614
   PubMed Web of Science ®Google Scholar
• Aviles A, Duque G, Talavera A, Guzman R. Interferon α2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996; 20: 495–499
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Carde P, Meerwaldt J H, Somers R, Thomas J, De Bock R, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998; 16: 41–47
   PubMed Web of Science ®Google Scholar
• Arranz R, Garcia-Alfonso P, Sobrino P, Zamora P, Carrion R, Garcia-Larana J, et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998; 16: 1538–1546
   PubMed Web of Science ®Google Scholar
• Fisher R I, Dana B W, LeBlanc M, Kjeldsberg C, Forman J D, Unger J M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000; 18: 2010–2016
   PubMed Web of Science ®Google Scholar
• Rohatiner A, Radford J, Deakin D, Earl H, Love S B, Price O, et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001; 85: 29–35
   PubMed Web of Science ®Google Scholar
• Peterson B A, Petroni G R, Oken M M, et al. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: an intergroup phase III trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol. 1997; 14a, Abstract 48
   Google Scholar
• Cheson B D. The curious case of the baffling biological. J Clin Oncol 2000; 18: 2007–2009
   PubMed Web of Science ®Google Scholar
• Tse W W, Lazarus H M, van Besien K. Stem cell transplantation in follicular lymphoma: progress at last?. Bone Marrow Transplant 2004; 34: 929–938
   PubMed Web of Science ®Google Scholar
• van Besien K, Loberiza F R, Bajorunaite R, Armitage J O, Bashey A, Burns L J, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460–1468
   PubMed Web of Science ®Google Scholar
• Bierman P J, Sweetenham J W, Loberiza F M, Zhang M J, Ballen K K, Bashey A, et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation. J Clin Oncol 2003; 3744–3753
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma – results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2004; 104: 2667–2674
   PubMed Web of Science ®Google Scholar
• Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105: 3817–3823
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared to CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the GELA. Blood 2006; 108: 2540–2544
   PubMed Web of Science ®Google Scholar
• Dillman R O. The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy. Curr Pharm Biotechnol 2001; 2: 293–300
   PubMedGoogle Scholar
• Nadler L M, Stashenko P, Hardy R, Kaplan W D, Button L N, Kufe D W, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40: 3147–3154
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez A J. Rituximab: an insider's historical perspective. Semin Oncol 2000; 27: 9–16
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Hagemeister F B, Grillo-Lopez A J. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999; 26: 79–87
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Gandhi M K, Marcus R E. Follicular lymphoma: time for a re-think?. Blood Rev 2005; 19: 165–178
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone – results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). ASH Annual Meeting Abstr 2004; 104: 584
   Google Scholar
• Salles G A, Foussard C, Nicolas M, Franck M, Chantal D, Thierry L, et al. Rituximab Added {alpha}IFN + CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: to first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. ASH Annual Meeting Abstr 2004; 104: 160
   Google Scholar
• Buske C, Hiddemann W. Rituximab maintenance therapy in indolent NHL: a clinical review. Leuk Res 2006; 30(Suppl1)S11–S15
   PubMed Web of Science ®Google Scholar
• Khouri I F, Saliba R M, Hosing C, Okoroji G J, Acholonu S, Anderlini P, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240–2247
   PubMed Web of Science ®Google Scholar
• Hoerr A L, Gao F, Hidalgo J, Tiwari D, Blum K A, Mathews V, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561–4566
   PubMed Web of Science ®Google Scholar
• Horwitz S M, Negrin R S, Blume K G, Breslin S, Stuart M J, Stockerl-Goldstein K E, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777–783
   PubMed Web of Science ®Google Scholar
• Gordon L I, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymph 2004; 5: 98–101
   PubMedGoogle Scholar
• Kaminski M S, Tuck M, Estes J, Kolstad A, Ross C W, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441–449
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Zasadny K R, Francis I R, Fenner M C, Ross C W, Milik A W, et al. Iodine-131-anti B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974–1981
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Thall A, Witzig T E, Vose J M, Younes A, Emmanouilides C, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23: 4390–4398
   PubMed Web of Science ®Google Scholar
• DeNardo G L. Concepts in radioimmunotherapy and immunotherapy: radioimmunotherapy from a Lym-1 perspective. Semin Oncol 2005; 32: S27–S35
   PubMed Web of Science ®Google Scholar
• Leonard J P, Coleman M, Ketas J, Ashe M, Fiore J M, Furman R R, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed/refractory non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 5044–5051
   PubMed Web of Science ®Google Scholar
• Hsu F J, Caspar C B, Czerwinski D, Kwak L W, Liles T M, Syrengelas A, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial. Blood 1997; 89: 3129–3135
   PubMed Web of Science ®Google Scholar
• Bendandi M, Gocke C D, Kobrin C B, Benko F A, Sternas L A, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171–1177
   PubMed Web of Science ®Google Scholar
• Waters J S, Webb A, Cunningham D, Clarke P A, Raynaud F, di Stefano F, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812–1823
   PubMed Web of Science ®Google Scholar
• Klasa R J. Targeting the proapoptotic factor bcl-2 in non-Hodgkin's lymphoma. Oncology 2004; 18: 25–31
   PubMedGoogle Scholar
• Walensky L D, Kung A L, Escher I, Malia T J, Barbuto S, Wright R D, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305: 1466–1470
   PubMed Web of Science ®Google Scholar
• Polo J M, Dell'Oso T, Ranuncolo S M, Cerchietti L, Beck D, Da Silva G F, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 2004; 10: 1329–1335
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Unterhalt M, Hiddemann W. In reply: should we transplant patients with indolent lymphoma. J Clin Oncol 2005; 23: 6264–6266
   Web of Science ®Google Scholar
• Liu Q, Fayad L, Cabanillas F, Hagemeister F B, Ayers G D, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582–1589
   PubMed Web of Science ®Google Scholar